Sacubitril/Valsartan Plus Ivabradine Improves Outcomes in CRS Patients: Study
Combination therapy with sacubitril/valsartan and ivabradine was effective in treating cardiorenal syndrome (CRS), showing superior improvement across multiple clinical indicators and a lower incidence of major adverse cardiovascular events (MACE).
A study was done to investigate the effects of sacubitril/valsartan combined with ivabradine in treating cardiorenal syndrome (CRS). Cardiorenal syndrome (CRS) represents a complex clinical condition in which dysfunction of the heart and kidneys is interlinked, often leading to progressive worsening of both organ systems. Managing CRS remains challenging because patients typically present with overlapping cardiac insufficiency, impaired renal perfusion, and metabolic disturbances that require therapies targeting multiple pathways simultaneously. In recent years, interest has grown in combination pharmacologic strategies that can address both hemodynamic stress and neurohormonal overactivation. In this context, sacubitril/valsartan, a dual angiotensin receptor–neprilysin inhibitor, has been shown to improve cardiac outcomes by enhancing natriuretic peptide activity while suppressing the renin–angiotensin system. Ivabradine, a selective heart rate–lowering agent acting on the sinoatrial node, offers additional benefits by reducing myocardial oxygen demand without negatively affecting contractility.Given these complementary mechanisms, a retrospective study involving 120 patients was conducted to evaluate whether adding ivabradine to sacubitril/valsartan therapy provides superior clinical benefits compared with sacubitril/valsartan alone in patients with CRS.
Information from 120 selected participants was retrospectively analyzed and divided into an experimental group (n=60) and a control group (n=60). The control group received sacubitril/valsartan alone, while the experimental group received sacubitril/valsartan plus ivabradine. Clinical efficacy, blood lipids, cardiac and renal function, and oxidative stress were observed in both groups. The experimental group showed better clinical efficacy, lipid metabolism, cardiac function, renal function, and oxidative stress than the control group, and a lower incidence of major adverse cardiovascular events (MACE) (all P<0.05). Sacubitril/valsartan combined with ivabradine is effective in treating CRS patients, with superior efficacy across various indicators and its usage has a lower incidence of MACE.
Reference:
Li, Guilan, et al. "Effects of Sacubitril/valsartan Combined With Ivabradine in Treating Cardiorenal Syndrome." American Journal of Translational Research, vol. 18, no. 4, 2026, pp. 3201-3210.
KeywordS:
Sacubitril/Valsartan , Plus, Ivabradine, Improves, Outcome, CRS Patient, Study, Li, Guilan
